The Clorox Company (CLX) Stock Price & Analysis
The Clorox Company (CLX) closed at USD 88.66 on Thursday, October 22, 2026, up 4.59% on the day. The US market is currently closed (pre-market); this is not a live price.
The prior close was USD 88.66; the Oct 22, 2026 session ranged USD 85.18–88.7 on volume of 2,849,465 shares. Market capitalization is —, with a 52-week range of USD 79.12–128.9 (NYQ). Source: Nexqual, retrieved October 23, 2026 at 09:22 UTC.
Also available as compact Markdown for AI agents: nexqual.com/CLX.md
Key facts (CLX)
- Last four reported quarters (through Mar 31, 2026): revenue $6.76B, net income $756M (11.2% margin), free cash flow $380M (SEC filings).
- 5 of 80 tracked superinvestors hold CLX (13F, Q2 2026): 0 new, 2 added, 2 reduced, 1 unchanged.
- Total return with dividends: 1Y -21.1% vs S&P 500 +14.9%; 5Y -34.5% vs S&P 500 +80.3%.
- Next earnings: 2026-11-02, EPS estimate USD 1.07, revenue estimate $1.88B.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (CLX)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $7.34B | $7.11B | $7.39B | $7.09B | $7.10B | $6.76B |
| Gross profit | $3.20B | $2.54B | $2.91B | $3.05B | $3.21B | — |
| Net income | $710M | $462M | $149M | $280M | $810M | $756M |
| EPS (diluted) | $5.58 | $3.73 | $1.20 | $2.25 | $6.52 | — |
| Free cash flow | $945M | $535M | $930M | $483M | $761M | $380M |
| Gross margin | 43.6% | 35.8% | 39.4% | 43.0% | 45.2% | — |
| Net margin | 9.7% | 6.5% | 2.0% | 3.9% | 11.4% | 11.2% |
| Revenue growth | +9.2% | -3.2% | +4.0% | -4.0% | +0.2% | — |
| Cash + short-term investments | $319M | $183M | $367M | $202M | $167M | — |
| Total debt | $2.78B | $2.47B | $2.48B | $2.48B | $2.48B | — |
Fiscal years end Jun. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Mar 31, 2026) (CLX)
P/E at fiscal year-ends: Jun 2025 18.4x, Jun 2024 60.8x, Jun 2023 132.5x.
Superinvestors (SEC 13F-HR, Q2 2026) (CLX)
5 of 80 tracked investors hold CLX. Each row is the investor's latest 13F; change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| Hillman Capital | Hillman Capital Management | 0.24% | $337K | Reduced -0.7% |
| Terry Smith | Fundsmith | 0.19% | $25.9M | Added +5.5% |
| Jensen Investment Management | 0.11% | $4.6M | Added +3.5% | |
| Yacktman Asset Management | 0.06% | $4.6M | Unchanged | |
| Lee Ainslie | Maverick Capital | <0.01% | $349K | Reduced -77.8% |
Analysts (CLX)
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-19 | JP Morgan | Target lowered | Underweight | $95 → $83 |
| 2026-10-16 | Barclays | Target lowered | Underweight | $84 → $80 |
| 2026-10-15 | Morgan Stanley | Target lowered | Equal-Weight | $97 → $87 |
| 2026-10-14 | Citigroup | Target lowered | Neutral | $97 → $90 |
| 2026-10-13 | TD Cowen | Target lowered | Hold | $85 → $80 |
| 2026-10-05 | Wells Fargo | Target lowered | Equal-Weight | $90 → $85 |
| 2026-09-11 | Citigroup | Target lowered | Neutral | $100 → $97 |
| 2026-09-11 | Wells Fargo | Target lowered | Equal-Weight | $102 → $90 |
| 2026-08-04 | UBS | Target raised | Neutral | $100 → $105 |
| 2026-08-04 | JP Morgan | Target raised | Underweight | $92 → $95 |
| 2026-08-04 | Citigroup | Target raised | Neutral | $97 → $100 |
| 2026-08-04 | Wells Fargo | Target raised | Equal-Weight | $95 → $102 |
Total return (dividends reinvested) (CLX)
| 1Y (from 2025-10-23) | 5Y (from 2021-10-18) | |
|---|---|---|
| Total return | -21.1% | -34.5% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | -21.1% | -8.1% |
| Volatility (annualized) | 32.1% | 27.9% |
| Max drawdown | -35.2% (Feb 2026→Oct 2026) | -49.0% (Jan 2022→Sep 2026) |
CLX revenue by business segment (quarter ended Jun 30, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| Health and Wellness | $860.0M | 44.1% | +16.1% |
| Household | $524.0M | 26.9% | -18.0% |
| International | $281.0M | 14.4% | +4.5% |
| Lifestyle | $280.0M | 14.4% | -17.4% |
| Total revenue | $1.95B | 100% | — |
CLX revenue by region (fiscal year ended Jun 30, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| United States | $5.63B | 83.8% | -7.4% |
| Foreign | $1.09B | 16.2% | +6.5% |
| Total revenue | $6.72B | 100% | — |
As tagged by the company in its SEC 10-Q / 10-K filings (XBRL).
CLX suppliers, customers and competitors (named in its 10-K)
| Relationship | Company | Sentence in the filing |
|---|---|---|
| Partner | Procter & Gamble (PG) | “The Company's venture agreement with The Procter & Gamble Company (P&G) for the Company's Glad bags and wraps business (the Venture Agreement) expired on January 31, 2026.” |
Quoted from the company's 10-K filed Aug 7, 2026.
CLX customer concentration
In the period ended Jun 30, 2026, a single direct customer accounted for 26% of revenue, per the company's 10-K filed Aug 7, 2026. The company does not name it.
CLX company outlook (results filed Aug 3, 2026)
- “Delivers Q4 results in line with expectations while advancing strategic investments OAKLAND, California, Aug. 3, 2026 — The Clorox Company (NYSE: CLX) today reported results for the fourth quarter and fiscal year 2026, which ended June 30, 2026.”
- “The impact of ERP-related shipment comparison was about 90 cents. "Our fourth-quarter results were in line with our expectations and reflect disciplined execution in a dynamic environment," said Chair and CEO Linda Rendle. "Throughout fiscal year 2026, we strengthened our business despite continued consumer and macroeconomic pressures.”
Quoted word-for-word from the SEC 8-K results press release.
CLX analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $1.07 | $1.21 | -11.7% | $1.88B | 15 |
| Next quarter (ends Dec 2026) | $1.34 | $1.39 | -3.6% | $1.89B | 15 |
| Current fiscal year (ends Jun 2027) | $5.70 | $6.02 | -5.2% | $7.63B | 19 |
| Next fiscal year (ends Jun 2028) | $6.13 | $6.54 | -6.2% | $7.82B | 18 |
Key Statistics (as of October 23, 2026 at 09:22 UTC)
| Price | USD 88.66 |
|---|---|
| Change | ▲ 4.59% (up) |
| Previous Close | USD 88.66 |
| Open | USD 88.66 |
| Day Range | USD 85.18 – 88.7 |
| 52-Week Range | USD 79.12 – 128.9 |
| Volume | 2,849,465 shares |
| Market Cap | — |
| Exchange | NYQ |
Technical Analysis (CLX)
Nexqual's technical model rates CLX "SELL" based on 2 bullish and 5 bearish signals across 127 daily candles, as of October 23, 2026 at 09:22 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 55.23 (neutral) |
| vs SMA50 | Below (USD 90.87) |
| MACD | -0.51 (negative) |
Earnings (CLX)
| Next Earnings Date | 2026-11-02 |
|---|---|
| EPS Estimate | USD 1.07 |
| Revenue Estimate | $1.88B |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD 1.66 vs est 1.65 ▲ beat |
| 2026-03-31 | USD 1.64 vs est 1.54 ▲ beat |
| 2025-12-31 | USD 1.39 vs est 1.43 ▼ miss |
| 2025-09-30 | USD 0.85 vs est 0.78 ▲ beat |
Source: Nexqual, October 23, 2026 at 09:22 UTC.
Financials & Fundamentals (CLX)
| Total Revenue | $6.72B |
|---|---|
| Revenue Growth (latest quarter, YoY) | -2.00% |
| Gross Margin | +42.32% |
| Operating Margin | +12.88% |
| Profit Margin | +8.73% |
| ROE | +163.76% |
| Debt / Equity | 22.21 |
| Current Ratio | 0.66 |
| Total Cash | $143.00M |
| Total Debt | $5.60B |
Source: Nexqual, October 23, 2026 at 09:22 UTC.
Ownership (CLX)
| Insider Ownership | +0.69% |
|---|---|
| Institutional Ownership | +88.21% |
| Shares Outstanding | 120.94M |
| Float | 120.49M |
| Short % of Float | +11.04% |
Source: Nexqual, October 23, 2026 at 09:22 UTC.
From The Clorox Company's Latest SEC 10-K Filing (filed 2026-08-07)
Key Strengths & Strategy (as disclosed to the SEC)
- The Company also markets industry-leading products and technologies for professional customers, including those sold under the Purell®, CloroxPro™ and Clorox Healthcare® brand names.
- The ERP system implementation, which was completed in January 2026, has required, and will continue to require, investment of personnel and financial resources to support post-implementation efforts and system functionality.
Partnerships
- The Company's venture agreement with The Procter & Gamble Company (P&G) for the Company's Glad bags and wraps business (the Venture Agreement) expired on January 31, 2026.
- In connection with the expiration of the Venture Agreement, the Company was required to purchase P&G's 20% interest in the business at fair value.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ELF | e.l.f. Beauty, Inc. | USD 114.99 | ▲ 1.06% |
| CHD | Church & Dwight Company, Inc. | USD 108.86 | ▲ 3.68% |
| IPAR | Interparfums, Inc. | USD 116.07 | ▲ 2.54% |
| KMB | Kimberly-Clark Corporation | USD 112.32 | ▲ 5.32% |
| KVUE | Kenvue Inc. | USD 19.88 | ▲ 4.41% |
| EL | Estee Lauder Companies, Inc. (T | USD 107.72 | ▲ 3.92% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 09:22 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt